AMRI signs agreement with an Australian firm Parnell

ALBANY, US: AMRI announced it has signed a development and long term exclusive commercial supply agreement with Parnell Manufacturing Pty Ltd. Under the agreement, AMRI will provide process development, manufacturing and supply of active pharmaceutical ingredients (APIs) to support Parnell’s submission of a New Animal Drug Application (NADA) with the US Food and Drug Administration (FDA) and commercial launch of its veterinary product onto the US market pending regulatory approval. The development and manufacture of this API will take place at AMRI’s facilities in Albany, NY.

“Parnell sought expressions of interest for the development and long term supply of this API from several companies and we are pleased that AMRI was ultimately successful in their tender. This product is an extremely important project for Parnell and the FDA compliant development is paramount to the successful launch,” said Robert Joseph, CEO, Parnell.

© WOC News